TY - JOUR
KW - Colonic Neoplasms
KW - Humans
KW - Immunotherapy
KW - organoids
KW - Precision Medicine
KW - adoptive cell therapy
KW - bispecific antibody
KW - colorectal cancer
KW - droplet microfluidics
KW - immune-oncology
KW - lung cancer
KW - micro-organosphere
KW - Precision Medicine
KW - precision oncology
KW - tumorsphere
AU - Shengli Ding
AU - Carolyn Hsu
AU - Zhaohui Wang
AU - Naveen R. Natesh
AU - Rosemary Millen
AU - Marcos Negrete
AU - Nicholas Giroux
AU - Grecia O. Rivera
AU - Anders Dohlman
AU - Shree Bose
AU - Tomer Rotstein
AU - Kassandra Spiller
AU - Athena Yeung
AU - Zhiguo Sun
AU - Chongming Jiang
AU - Rui Xi
AU - Benjamin Wilkin
AU - Peggy M. Randon
AU - Ian Williamson
AU - Daniel A. Nelson
AU - Daniel Delubac
AU - Sehwa Oh
AU - Gabrielle Rupprecht
AU - James Isaacs
AU - Jingquan Jia
AU - Chao Chen
AU - John Paul Shen
AU - Scott Kopetz
AU - Shannon McCall
AU - Amber Smith
AU - Nikolche Gjorevski
AU - Antje-Christine Walz
AU - Scott Antonia
AU - Estelle Marrer-Berger
AU - Hans Clevers
AU - David Hsu
AU - Xiling Shen
AB - Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14 days, a timeline suitable for guiding treatment decisions in the clinic. Furthermore, MOSs capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.
BT - Cell Stem Cell
DA - 2022-06-02
DO - 10.1016/j.stem.2022.04.006
IS - 6
LA - eng
N2 - Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14 days, a timeline suitable for guiding treatment decisions in the clinic. Furthermore, MOSs capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.
PY - 2022
SP - 905
EP - 917.e6
T2 - Cell Stem Cell
TI - Patient-derived micro-organospheres enable clinical precision oncology
VL - 29
SN - 1875-9777
ER -